RxDoctor Payments Data

Christopher Sayed, MD

Dermatology · Chapel Hill, NCNPI 1225265903

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $511,871 of the $690,224 with a category attached, or 74.2%. AbbVie accounts for 85.9% of it on its own, with 12 other manufacturers making up the rest. Among dermatology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$690,224in general payments, 2019–2025

Across 515 payments — averaging $1340.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$593K
  • UCB, Inc.$27K
  • UCB SA$21K
  • Novartis$15K
  • Incyte Corporation$13K
  • UCB Biosciences Inc.$7K
  • plus $16K from 7 others
$2,617,733in research payments, 2019–2025

Across 535 payments — averaging $4892.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • UCB SA$1.1M
  • AstraZeneca$1M
  • Incyte Corporation$528K
  • Novartis Pharma AG$1K
  • UCB, Inc.$400
  • Novartis$324

What the payments were for

  • Consulting fees$104,45115%
  • Speaking & faculty fees$511,87174%
  • Travel & lodging$66,61010%
  • Food & beverage$7,2111%
  • Education$800%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$690,224 in reported general payments places this provider in the 95th percentile of 475 dermatology providers in North Carolina.

See all dermatology providers in North Carolina

Medicare billing

Part B allowed, 2024
$41,363
Medicare patients
135
Services billed
714

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab86$1,487,300
Cosentyx Unoready PenSecukinumab87$1,096,162
RemicadeInfliximab47$699,614
StelaraUstekinumab20$529,624
Bimzelx AutoinjectorBimekizumab-Bkzx13$334,227
InflectraInfliximab-Dyyb23$175,257
Taltz AutoinjectorIxekizumab11$104,263
ErtapenemErtapenem Sodium49$18,352
Cefdinir37$2,343
Doxycycline Hyclate49$1,906
Tacrolimus11$1,501
Clobetasol Propionate30$1,459
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav43$1,410
Clindamycin Hcl37$1,109
Metronidazole21$870

Paid to pharmacies, not to this prescriber.

Other dermatology in Chapel Hill

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →